OGI Nasdaq Pharmaceutical Preparations Financials FY2018βFY2025
Organigram Global Inc. had $185M of revenue in fiscal 2025. Over five years, revenue changed +23.5% a year on average.
Hi! I read Organigram Global Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Does it make a profit?
β9.6%
No. It lost money last year.
Does profit turn into cash?
β9.5%
No. It spent more cash than it brought in.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Organigram Global Inc. had $185M of revenue in fiscal 2025. Over five years, revenue changed +23.5% a year on average. Its operating margin was β5.9%: of every 100 in sales, about β6 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Organigram Global Inc. lost $17.7M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$17.6M in fiscal 2025, β9.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Organigram Global Inc. has $60.0M more cash than debt.
Cash, debt and the ratios that show how comfortably Organigram Global Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY20 | FY21 | FY22 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | β | β | β | $98.1M | $60.0M |
| Debt incl. finance leases | $88.2M | $0.2M | $0.2M | $0.0M | $0.0M |
| Debt / equity | 0.4x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | β24.2x | β31.0x | β100.6x | β | β |
| Current ratio | 5.9x | 9.9x | 4.0x | 4.9x | 2.3x |
| Quick ratio | 3.6x | 8.5x | 3.1x | 3.7x | 1.4x |
| Total assets | $333M | $440M | $440M | $302M | $404M |
| Total liabilities | $104M | $59.0M | $52.7M | $75.4M | $153M |
| Shareholders' equity | $229M | $381M | $388M | $226M | $251M |
| Net debt (β = net cash) | β | β | β | β$98.1M | β$60.0M |
KIRA Β· Its return on capital was β4.5%: every 100 invested in the business earned about β5 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 1 / 9 | 3 / 9 | 5 / 9 | 5 / 9 | β / 5 |
| Accruals ratio | 11.2% | 6.9% | β20.6% | β20.8% | 3.9% | β3.5% |
| Altman Z'' | 6.64 | 5.73 | 1.18 | 6.84 | 7.46 | β0.14 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $9.7M | $60.7M | $64.5M | $62.4M | $115M | β | $185M |
| Provision for credit losses | β | β | β | β | $0.2M | β | β |
| Gross profit | $40.4M | $36.6M | β$42.0M | β$22.4M | $24.8M | β | $64.5M |
| Research and development | $0.0M | $0.3M | $0.9M | $2.9M | $4.7M | β | $7.8M |
| Operating income | $28.5M | $4.1M | β$108M | β$72.4M | β$33.9M | β | β$10.9M |
| Interest expense | $7.9M | $7.3M | $4.5M | $2.3M | $0.3M | β | β |
| Pretax income | $21.7M | β$4.4M | β$109M | β$103M | β$11.3M | β | β$27.5M |
| Income tax | $4.4M | $2.7M | β$7.8M | $0.0M | β$0.1M | β | β$9.8M |
| Net income | $16.1M | β$7.2M | β$101M | β$103M | β$11.2M | β | β$17.7M |
| Diluted EPS | $0.13 | β$0.05 | β$0.59 | β$0.40 | β$0.14 | β | β$0.14 |
| Diluted shares | 0.13B | 0.15B | 0.18B | 0.26B | 0.08B | β | 0.13B |
| Cash flow | |||||||
| Cash from operations | β$9.9M | β$26.5M | β$33.5M | β$22.5M | β$28.5M | β | β$5.4M |
| Capital expenditure | $44.2M | $82.1M | $57.4M | $9.3M | $38.3M | β | $12.2M |
| Free cash flow | β$54.1M | β$109M | β$90.9M | β$31.8M | β$66.8M | β | β$17.6M |
| Depreciation and amortization | $0.4M | $0.5M | $1.1M | $1.9M | $4.2M | β | $5.5M |
| Stock-based compensation | $3.9M | $11.2M | $5.8M | $3.1M | $4.0M | β | $3.0M |
| Acquisitions | β | β | β | β | β | β | $46.9M |
| Balance sheet | |||||||
| Cash and short-term investments | β | β | β | β | β | $98.1M | $60.0M |
| Total debt | $2.5M | $37.3M | $88.2M | $0.2M | $0.2M | $0.0M | $0.0M |
| Current assets | $156M | $148M | $130M | $207M | $169M | $194M | $205M |
| Current liabilities | $8.6M | $33.0M | $22.3M | $20.9M | $42.2M | $39.4M | $90.6M |
| Inventory | $34.5M | $70.1M | $50.8M | $29.2M | $38.4M | $49.8M | $76.2M |
| Property and equipment, net | $75.6M | $164M | $189M | $187M | $198M | $71.2M | β |
| Goodwill | β | β | β | β | β | $0.0M | $37.7M |
| Intangible assets | $0.0M | $1.6M | $1.4M | $13.5M | $42.9M | $6.0M | $34.8M |
| Total assets | $232M | $323M | $333M | $440M | $440M | $302M | $404M |
| Total liabilities | $90.5M | $76.4M | $104M | $59.0M | $52.7M | $75.4M | $153M |
| Shareholders' equity | $142M | $246M | $229M | $381M | $388M | $226M | $251M |
| Margins | |||||||
| Gross margin | 415.4% | 60.3% | β65.1% | β35.9% | 21.7% | β | 34.8% |
| Operating margin | 293.0% | 6.8% | β167.6% | β116.0% | β29.6% | β | β5.9% |
| EBITDA margin | 297.1% | 7.6% | β165.9% | β112.9% | β26.0% | β | β2.9% |
| Net margin | 165.0% | β11.9% | β156.9% | β165.1% | β9.8% | β | β9.6% |
| FCF margin | β556.3% | β178.9% | β141.0% | β51.0% | β58.3% | β | β9.5% |
| Returns | |||||||
| Return on capital | β | β | β | β | β | β | β4.5% |
| Return on capital employed | 12.8% | 1.4% | β34.8% | β17.3% | β8.5% | β | β3.5% |
| Return on equity | 11.3% | β3.7% | β42.6% | β33.7% | β2.9% | β | β7.4% |
| Return on assets | 6.9% | β2.6% | β30.9% | β26.6% | β2.6% | β | β5.0% |
| Return on tangible equity | 11.3% | β2.9% | β44.4% | β28.0% | β3.3% | β | β9.9% |
| Growth | |||||||
| Revenue growth | β | 523.4% | 6.3% | β3.3% | 83.8% | β | β |
| Net income growth | β | β144.8% | β | β | β | β | β |
| EPS growth | β | β140.5% | β | β | β | β | β |
| Share count change | β | 19.5% | 17.5% | 43.8% | β69.8% | β | β |
| Financial health | |||||||
| Debt / equity | 0.0x | 0.2x | 0.4x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | 3.6x | 0.6x | β24.2x | β31.0x | β100.6x | β | β |
| Current ratio | 18.1x | 4.5x | 5.9x | 9.9x | 4.0x | 4.9x | 2.3x |
| Quick ratio | 14.1x | 2.4x | 3.6x | 8.5x | 3.1x | 3.7x | 1.4x |
| Capital allocation | |||||||
| Capex / revenue | 454.1% | 135.3% | 89.0% | 14.9% | 33.4% | β | 6.6% |
| Stock comp / revenue | 40.5% | 18.5% | 9.0% | 4.9% | 3.5% | β | 1.6% |
| Quality scores | |||||||
| Piotroski F-score | β | 1.0 | 3.0 | 5.0 | 5.0 | β | β |
| Altman Z'' | 6.6 | 5.7 | 1.2 | 6.8 | 7.5 | β | β0.1 |
| Accruals ratio | 11.2% | 6.9% | β20.6% | β20.8% | 3.9% | β | β3.5% |
Source: SEC EDGAR XBRL filings (CIK 0001620737). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CAD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only β not investment advice. Check the original filings before relying on any figure.
